Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets

Nathan M Kendsersky,Michal Odrobina,Nathaniel W Mabe,Alvin Farrel,Liron Grossmann,Matthew Tsang,Adam J Wolpaw,Francesca Zammarchi,Patrick H van Berkel,Chi V Dang,Yael P Mosse,Kimberly Stegmaier,John Maris
DOI: https://doi.org/10.1101/2024.06.27.600865
2024-07-02
Abstract:Background: Neuroblastoma is a heterogeneous disease with adrenergic (ADRN)- and therapy resistant mesenchymal (MES)-like cells driven by distinct transcription factor networks. Here, we investigate the expression of immunotherapeutic targets in each neuroblastoma subtype and propose pan-neuroblastoma and cell state specific targetable cell-surface proteins. Methods: We characterized cell lines, patient-derived xenografts, and patient samples as ADRN-dominant or MESdominant to define subtype-specific and pan-neuroblastoma gene sets. Targets were validated with ChIPsequencing, immunoblotting, and flow cytometry in neuroblastoma cell lines and isogenic ADRN-to-MES transition cell line models. Finally, we evaluated the activity of MES-specific agents in vivo and in vitro. Results: Most immunotherapeutic targets being developed for neuroblastoma showed significantly higher expression in the ADRN subtype with limited expression in MES-like tumor cells. In contrast, CD276 (B7-H3) and L1CAM maintained expression across both ADRN and MES states. We identified several receptor tyrosine kinases (RTKs) enriched in MES-dominant samples and showed that AXL targeting with ADCT-601 was potently cytotoxic in MES-dominant cell lines and showed specific anti-tumor activity in a MES cell line-derived xenograft. Conclusions: Immunotherapeutic strategies for neuroblastoma must address the potential of epigenetic downregulation of antigen density as a mechanism for immune evasion. We identified several RTKs as candidate MES-specific immunotherapeutic target proteins for the elimination of therapy-resistant cells. We hypothesize that the phenomena of immune escape will be less likely when targeting pan-neuroblastoma cell surface proteins such as B7-H3 and L1CAM, and/or dual targeting strategies that consider both the ADRN- and MES-cell states.
Cancer Biology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is the influence of different cell states in neuroblastoma on the expression of immunotherapy targets. Specifically, the research focuses on: 1. **Identification of cell - state - dependent immunotherapy targets**: Neuroblastoma is heterogeneous and is mainly divided into two subtypes: adrenergic (ADRN) and mesenchymal (MES). These two subtypes are driven by different transcription factor networks and show significant epigenetic differences. The paper aims to identify the immunotherapy targets expressed in each subtype and propose cell - surface proteins applicable to all neuroblastoma subtypes or specific subtypes as potential treatment targets. 2. **Discussion of immune evasion mechanisms**: Many neuroblastoma immunotherapy targets under development are highly expressed in the ADRN subtype but have limited expression in the MES subtype. This difference may lead to MES - subtype tumor cells escaping recognition and attack by the immune system through epigenetic down - regulation of antigen density. Therefore, the research also explores how to avoid or overcome this immune evasion phenomenon by selecting appropriate targets. 3. **Proposal of new immunotherapy strategies**: The research has discovered several receptor tyrosine kinases (RTKs) enriched in the MES subtype, such as AXL, and has verified the effectiveness and specific anti - tumor activity of antibody - drug conjugates (ADCs) targeting these targets in MES - subtype cells. In addition, the research also points out that cell - surface proteins such as B7 - H3 (CD276) and L1CAM, which are expressed across subtypes, may be more ideal immunotherapy targets because they maintain relatively high expression levels in both subtypes. In summary, the core objective of this paper is to provide a scientific basis for the development of more effective immunotherapy strategies by in - depth analysis of different cell states in neuroblastoma and their influence on the expression of immunotherapy targets, especially for those MES - subtype tumor cells that are prone to drug resistance. This helps to improve the effectiveness of immunotherapy and reduce the possibility of immune evasion. ### Key findings: - **Differences in immunotherapy targets between ADRN and MES subtypes**: Most immunotherapy targets are highly expressed in the ADRN subtype but have lower expression in the MES subtype. - **Targets expressed across subtypes**: B7 - H3 (CD276) and L1CAM maintain relatively high expression in both ADRN and MES subtypes and may become immunotherapy targets for pan - neuroblastoma. - **MES - subtype - specific targets**: RTKs such as AXL are enriched in the MES subtype and may be MES - subtype - specific immunotherapy targets. ### Research methods: - **RNA - sequencing data analysis**: Used to classify neuroblastoma samples and identify subtype - specific and pan - subtype genes. - **ChIP - sequencing and DNA methylation analysis**: To verify the epigenetic regulation of subtype - specific genes. - **Cell experiments and animal model experiments**: To evaluate the therapeutic effects of candidate targets in vitro and in vivo. ### Conclusions: - Immunotherapy strategies should consider cell - state changes in neuroblastoma, especially the down - regulation of antigen density caused by epigenetic regulation. - Targeting targets expressed across subtypes (such as B7 - H3 and L1CAM) or a dual - targeting strategy combining ADRN and MES subtypes may be more effective. - MES - subtype - specific targets (such as AXL) may be an effective way to eliminate drug - resistant cells.